Xiamen Amoytop Biotech Co., Ltd.
Clinical trials sponsored by Xiamen Amoytop Biotech Co., Ltd., explained in plain language.
-
Weekly shot could replace daily growth hormone for short kids born small
Disease control Recruiting nowThis study tests a new once-weekly growth hormone injection (inpegsomatropin) against the standard daily growth hormone shot in 141 children born small for gestational age who remain short. The goal is to see if the weekly shot works as well or better at helping kids grow taller …
Phase: PHASE3 • Sponsor: Xiamen Amoytop Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Weekly shot could replace daily needles for short kids
Disease control Recruiting nowThis study tests a new growth hormone medicine (inpegsomatropin) given once a week compared to the standard daily growth hormone shot. About 300 children with idiopathic short stature (short for no known medical reason) will receive either the weekly or daily injection for one ye…
Phase: PHASE3 • Sponsor: Xiamen Amoytop Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Experimental drug aims to tame overactive platelet production
Disease control Recruiting nowThis phase 2 trial tests two doses of peginterferon alfa-2b in 27 adults with essential thrombocythemia, a blood disorder causing too many platelets, who did not respond to or could not tolerate standard therapy. Participants receive weekly injections for up to 96 weeks. The stud…
Phase: PHASE2 • Sponsor: Xiamen Amoytop Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC